Journal of Dental Research, Vol 66, 1310-1314, Copyright © 1987 by International & American Associations for Dental Research Online Journals

ARTICLES

A non-antibacterial chemically-modified tetracycline inhibits mammalian collagenase activity

L. M. Golub, T. F. McNamara, G. D'Angelo, R. A. Greenwald and N. S. Ramamurthy

Tetracyclines (including the semi-synthetic analogues, minocycline and doxycycline) are considered useful adjuncts in periodontal therapy because they suppress Gram-negative periodontopathogens. Recently, these antibiotics were found to inhibit mammalian collagenase activity, a property which may also be of therapeutic value. It has been suggested that the anti-collagenase properties of the tetracyclines are independent of their antibiotic efficacy. To advance this hypothesis further, we chemically converted tetracycline hydrochloride to its non-antimicrobial analogue, de-dimethylaminotetracycline. This chemically-modified tetracycline (CMT), although no longer an effective antibiotic, was found to inhibit the in vitro activity of collagenase from partially purified extracts of human rheumatoid synovial tissue and rachitic rat epiphysis. In a preliminary in vivo study, pathologically-excessive collagenase in skin and gingiva was induced by rendering adult male rats diabetic, and the oral administration of CMT to these rats significantly reduced the excessive collagenase activity in both tissues. Moreover, CMT administration did not affect the severe hyperglycemia in these rats but did prevent, at least in part, the diabetes-induced loss of body weight, skin weight, and skin collagen mass; these effects suggest a lack of toxicity in this animal model. A proposed clinical advantage of CMT over conventional tetracyclines, in the treatment of diseases characterized by excessive collagenolytic activity, is the lack of development of antibiotic-resistant micro-organisms during prolonged use. However, the consideration of clinical trials to support this hypothesis must await further laboratory and extensive toxicity tests.

This article has been cited by other articles:

				S. D. Young, M. Whissell, J. C.S. Noble, P. O. Cano, P. G. Lopez, and C. J. Germond Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors. Clin. Cancer Res., May 15, 2006; 12(10): 3092 - 3098. [Abstract] [Full Text] [PDF]

				S. S. Kocer, S. G. Walker, B. Zerler, L. M. Golub, and S. R. Simon Metalloproteinase Inhibitors, Nonantimicrobial Chemically Modified Tetracyclines, and Ilomastat Block Bacillus anthracis Lethal Factor Activity in Viable Cells Infect. Immun., November 1, 2005; 73(11): 7548 - 7557. [Abstract] [Full Text] [PDF]

				S. G. CIANCIO Medications' impact on oral health J Am Dent Assoc, October 1, 2004; 135(10): 1440 - 1448. [Abstract] [Full Text] [PDF]

				C. Zhang, B. Lei, T. T. Lam, F. Yang, D. Sinha, and M. O. M. Tso Neuroprotection of Photoreceptors by Minocycline in Light-Induced Retinal Degeneration Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2753 - 2759. [Abstract] [Full Text] [PDF]

				R. Skidmore, R. Kovach, C. Walker, J. Thomas, M. Bradshaw, J. Leyden, C. Powala, and R. Ashley Effects of Subantimicrobial-Dose Doxycycline in the Treatment of Moderate Acne Arch Dermatol, April 1, 2003; 139(4): 459 - 464. [Abstract] [Full Text] [PDF]

				Y. Liu, M. E. Ryan, H.-M. Lee, S. Simon, G. Tortora, C. Lauzon, M. K. Leung, and L. M. Golub A Chemically Modified Tetracycline (CMT-3) Is a New Antifungal Agent Antimicrob. Agents Chemother., May 1, 2002; 46(5): 1447 - 1454. [Abstract] [Full Text] [PDF]

				R. N. Patel, M. G. Attur, M. N. Dave, I. V. Patel, S. A. Stuchin, S. B. Abramson, and A. R. Amin A Novel Mechanism of Action of Chemically Modified Tetracyclines: Inhibition of COX-2-Mediated Prostaglandin E2 Production J. Immunol., September 15, 1999; 163(6): 3459 - 3467. [Abstract] [Full Text] [PDF]

				R. W. THOMPSON and B. T. BAXTER MMP Inhibition in Abdominal Aortic Aneurysms: Rationale for a Prospective Randomized Clinical Trial Ann. N.Y. Acad. Sci., June 30, 1999; 878(1): 159 - 178. [Abstract] [Full Text] [PDF]

				L. M. GOLUB, N. S. RAMAMURTHY, A. LLAVANERAS, M. E. RYAN, H. M. LEE, Y. LIU, S. BAIN, and T. SORSA A Chemically Modified Nonantimicrobial Tetracycline (CMT-8) Inhibits Gingival Matrix Metalloproteinases, Periodontal Breakdown, and Extra-Oral Bone Loss in Ovariectomized Rats Ann. N.Y. Acad. Sci., June 30, 1999; 878(1): 290 - 310. [Abstract] [Full Text] [PDF]

				J. F. WOESSNER Jr. Matrix Metalloproteinase Inhibition: From The Jurassic To The Third Millennium Ann. N.Y. Acad. Sci., June 30, 1999; 878(1): 388 - 403. [Abstract] [Full Text] [PDF]